Company intelligence / Profile preview

InnoTherapy

Ownership: Private
Development stage: Commercial

Overview

InnoTherapy has commercialized several bio-inspired hemostatic agents and surgical sealants that are used clinically in Korea and internationally. Products such as Hemoleast and InnoSEAL have demonstrated efficacy in controlling surgical bleeding. The company continues to expand its product line with novel formulations targeting various clinical needs.

Therapeutic areas: OtherDermatologyHematology
Modalities: DeviceProteinNanotechnology
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on InnoTherapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoTherapy.

Explore the full profile